U.S. gives Johnson & Johnson's COVID-19 vaccine a timeout

Out of an abundance of caution, the FDA and CDC have recommended a pause in the use of the only one-dose coronavirus vaccine available in the U.S. right now.

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The third coronavirus vaccine authorized for emergency use in the United States is going to sit in the corner by itself for a little while. On Tuesday morning, the Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement regarding Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.

The agencies recommended that health care providers pause their use of Johnson & Johnson's vaccine until an advisory committee can review six cases in which inoculations were followed by dangerous blood clots. All six occurred in women between the ages of 18 and 48 years old. Most importantly, they were associated with a low concentration of blood platelets.

If there is an associated risk, it's an extremely small one. As of Monday, more than 6.8 million people had received Johnson & Johnson's COVID-19 vaccine.

At a rate of less than one patient in a million, this pause might seem like an excessive overabundance of caution. The agencies won't please anyone with this decision, but they really don't have another option.

Both AstraZeneca's (NASDAQ: AZN) COVID-19 vaccine and Johnson & Johnson's employ a non-replicating virus that delivers genetic instructions. The European Medicines Agency recently said unusual blood clots that present in combination with low platelet levels should be listed as a very rare side effect of AstraZeneca's COVID-19 vaccine after assessing dozens of cases similar to the six reported in association with J&J's vaccine.

Blood clots that break free and travel to the blood vessels that serve the heart and other organ systems can be fatal. Strong blood thinners are standard treatments for dangerous clots, but giving those to patients with low platelet concentrations can be just as dangerous. 

The Advisory Committee on Immunization Practices will meet on Wednesday, so based on its determination, injections with Johnson & Johnson's vaccine could be allowed to resume before the end of the week.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Digital rocket on a laptop.
Broker Notes

Is the Nvidia share price on course to reach US$1,400?

You betcha, says one analyst.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Could Nvidia become the most valuable stock on earth?

Can anything stop the Nvidia stock price?

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
International Stock News

What can ASX investors learn from Warren Buffett's latest buys and sells?

We've just found out what Buffett's been buying and selling recently.

Read more »

electric vehicle such as Tesla being charged at charging station
International Stock News

Why Tesla stock tanked in January

Will the electric vehicle leader see earnings decline once again in 2024?

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Will Nvidia stock be worth more than Microsoft by 2030?

The graphics giant has been growing at a much faster pace than Microsoft, but can it sustain that momentum?

Read more »

Man with hands in the middle of two items with money bags on them.
International Stock News

Stock-split watch: Is Tesla next?

Stock splits are fun. But how much substance there is in Tesla splitting its stock is debatable.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
International Stock News

Yes, Microsoft is a star AI stock, but this is what really powered its solid second-quarter results

Deep involvement with artificial intelligence (AI) has made the company popular with investors, but that isn't (yet) the top motor…

Read more »

Search toolbar with a finger pointing to it.
International Stock News

Why Alphabet stock was sliding today

Shares of the tech giant pulled back on weaker-than-expected ad revenue in its fourth-quarter report.

Read more »